Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global, Multi-center, Randomized, Double-Blind, Placebo-controlled, Phase III Clinical Study to Evaluate the Protective Efficacy, Safety and Immunogenicity of SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine in Population Aged 18 Years and Older

NCT04847102 is registered in ClinicalTrials.gov with Walvax Biotechnology Co., Ltd. as lead sponsor.

NCT NCT04847102
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04847102 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global, Multi-center, Randomized, Double-Blind, Placebo-controlled, Phase III Clinical Study to Evaluate the Protective Efficacy, Safety and Immunogenicity of SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine in Population Aged 18 Years and Older
Lead sponsor
Walvax Biotechnology Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
July 22, 2021
Completion date
May 30, 2023
Enrollment
28,000 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov-2